NEW YORK — Rapid Labs has acquired the worldwide rights to manufacture and supply RNAssist's GenoPhix and VivoPhix sample preparation products, the UK companies said on Wednesday.
GenoPhix and VivoPhix are designed for biomolecule stabilization, tissue fixation, and microbial inactivation in a range of applications including RNA sequencing, single-cell DNA sequencing, metagenomics, and sample staining.
Under the terms of the deal, Rapid Labs will manufacture, market, and supply the products globally for research use only purposes. Additional terms were not disclosed.
"Our extensive network of customers, distributors, agents, and NGOs across the world will offer a substantial platform for introducing RNAssist products into the global scientific market," Rapid Labs CEO Ian Christopher said in a statement.